➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Moodys
Mallinckrodt
Colorcon
McKesson

Last Updated: March 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALLIUM GA-68 PSMA-11

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Gallium Ga-68 Psma-11

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002543 Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1995-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor.
NCT00002543 Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors Completed Medical College of Wisconsin Phase 1 1995-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor.
NCT00002578 Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 1994-08-01 RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.
NCT00002578 Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma Completed Roswell Park Cancer Institute Phase 2 1994-08-01 RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.
NCT00004010 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 2 1999-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
NCT00004010 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed Children's Oncology Group Phase 2 1999-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
NCT00038883 Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies Completed Leudosite N/A 2001-04-01 High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gallium Ga-68 Psma-11

Condition Name

Condition Name for Gallium Ga-68 Psma-11
Intervention Trials
Prostate Cancer 14
Lymphoma 13
Neuroendocrine Tumors 7
Prostate Adenocarcinoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gallium Ga-68 Psma-11
Intervention Trials
Prostatic Neoplasms 27
Neuroendocrine Tumors 16
Lymphoma 15
Carcinoma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gallium Ga-68 Psma-11

Trials by Country

Trials by Country for Gallium Ga-68 Psma-11
Location Trials
United States 126
Canada 7
Italy 6
France 6
Australia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gallium Ga-68 Psma-11
Location Trials
California 31
Texas 13
Iowa 7
Maryland 6
Washington 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gallium Ga-68 Psma-11

Clinical Trial Phase

Clinical Trial Phase for Gallium Ga-68 Psma-11
Clinical Trial Phase Trials
Phase 4 1
Phase 3 10
Phase 2/Phase 3 6
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gallium Ga-68 Psma-11
Clinical Trial Phase Trials
Recruiting 33
Not yet recruiting 31
Completed 13
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gallium Ga-68 Psma-11

Sponsor Name

Sponsor Name for Gallium Ga-68 Psma-11
Sponsor Trials
National Cancer Institute (NCI) 24
M.D. Anderson Cancer Center 11
University of California, San Francisco 9
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gallium Ga-68 Psma-11
Sponsor Trials
Other 106
NIH 27
Industry 22
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Express Scripts
Moodys
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.